	1 2
European Journal of Medicinal Chemistry	European Journal of Medicinal Chemistry, 2, 20% European Journal of Medicinal Chemistry 2 publications, 20%
Cancer Biology and Therapy	Cancer Biology and Therapy, 1, 10% Cancer Biology and Therapy 1 publication, 10%
Biochemical Pharmacology	Biochemical Pharmacology, 1, 10% Biochemical Pharmacology 1 publication, 10%
Chemistry and Biodiversity	Chemistry and Biodiversity, 1, 10% Chemistry and Biodiversity 1 publication, 10%
Pharmacogenomics and Personalized Medicine	Pharmacogenomics and Personalized Medicine, 1, 10% Pharmacogenomics and Personalized Medicine 1 publication, 10%
Russian Chemical Reviews	Russian Chemical Reviews, 1, 10% Russian Chemical Reviews 1 publication, 10%
Cell Cycle	Cell Cycle, 1, 10% Cell Cycle 1 publication, 10%
RSC Medicinal Chemistry	RSC Medicinal Chemistry, 1, 10% RSC Medicinal Chemistry 1 publication, 10%
Cancer Letters	Cancer Letters, 1, 10% Cancer Letters 1 publication, 10%
	1 2

Publishers

	1 2 3 4
Elsevier	Elsevier, 4, 40% Elsevier 4 publications, 40%
Taylor & Francis	Taylor & Francis, 3, 30% Taylor & Francis 3 publications, 30%
Wiley	Wiley, 1, 10% Wiley 1 publication, 10%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 10% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 1 publication, 10%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 1, 10% Royal Society of Chemistry (RSC) 1 publication, 10%
	1 2 3 4

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

RUFF J. et al. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death // Anticancer Research. 2021. Vol. 41. No. 12. pp. 5973-5985.

GOST all authors (up to 50) Copy

RUFF J., KRETZ A., KORNMANN M., HENNE-BRUNS D., LEMKE J., TRAUB B. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death // Anticancer Research. 2021. Vol. 41. No. 12. pp. 5973-5985.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.21873/anticanres.15416

UR - https://doi.org/10.21873/anticanres.15416

TI - The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death

T2 - Anticancer Research

AU - RUFF, J

AU - KRETZ, A

AU - KORNMANN, M

AU - HENNE-BRUNS, D

AU - LEMKE, J

AU - TRAUB, B

PY - 2021

DA - 2021/11/30

PB - Anticancer Research USA Inc.

SP - 5973-5985

IS - 12

VL - 41

PMID - 34848451

SN - 0250-7005

SN - 1791-7530

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2021_RUFF,

author = {J RUFF and A KRETZ and M KORNMANN and D HENNE-BRUNS and J LEMKE and B TRAUB},

title = {The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death},

journal = {Anticancer Research},

year = {2021},

volume = {41},

publisher = {Anticancer Research USA Inc.},

month = {nov},

url = {https://doi.org/10.21873/anticanres.15416},

number = {12},

pages = {5973--5985},

doi = {10.21873/anticanres.15416}

}

MLA

Cite this

MLA Copy

RUFF, J., et al. “The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death.” Anticancer Research, vol. 41, no. 12, Nov. 2021, pp. 5973-5985. https://doi.org/10.21873/anticanres.15416.

Publisher

Anticancer Research USA Inc.

Journal

Anticancer Research

scimago Q2

wos Q4

SJR

0.545

CiteScore

3.2

Impact factor

1.7

ISSN

02507005 (Print)

17917530 (Electronic)